April 1, 2022
The Next Big Thing in Pharma
Bill Thelin, Ph.D, Chief Scientific Officer at Altis Biosystems discusses the future of healthcare, and what's the next big thing in pharma. Bill focuses on how the development of microphysiological systems will support the development of drugs from discovery to humans.
March 31, 2022
A Human HTS Platform for Assessing Gastrointestinal Toxicity (GIT) Risk in Early Development
There is a significant unmet need for human models of GI risk assessment that can be utilized for drug optimization in early development.
February 16, 2022
A Novel, High-Throughput Platform to Characterize Novel IBD Therapeutics
Tumor Necrosis Factor Alpha (TNF-a) is a potent cytokine that is over-expressed by cells during chronic intestinal inflammation. Furthermore, TNF-a represents the most validated clinical target for ulcerative colitis (UC) and inflammatory bowel diseases (IBD) with multiple emerging neutralizing/inflammation-reducing therapeutics targeting this cytokine for inactivation. TNF-a activation of intestinal epithelia can disrupt the intestinal barrier via mechanisms including that activation of the inflammatory master regulators, including NFkB-induced IL-8 production and secretion, as well as having direct effects on tight junction integrity and cellular apoptosis.
November 4, 2021
Webinar: Studying the Responses to Cytokines Using Novel In Vitro Stem Cell Platforms
Many promising new drugs fail human clinical trials due to a lack of efficacy or unanticipated toxicity. More predictive non-clinical models that reprise human physiology and accurately evaluate drug pharmacokinetics and safety are urgently needed. Building on organ-on-a-chip technology, researchers developed an intestine-on-a-chip that recapitulates the human gut. In this webinar, Bill Thelin, Ph.D, Chief Scientific Officer, Altis Biosystems discusses how intestine-on-a chip technology reliably models gastrointestinal disease and assists researchers in screening for safe, effective therapeutic candidates.
August 5, 2021
The Power Of RepliGut® In Vitro Intestinal Stem Cell Models
Both current in vitro and in vivo models used in the development of candidate therapies for the treatment of intestinal diseases have severe limitations. RepliGut®, an in vitro human intestinal epithelial stem cell model, addresses many of these issues and has significant potential to reduce the time and cost of drug development. This model may even help to identify optimal therapies for individual patients.